SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Huaizhong Health Group, Inc. – ‘CORRESP’ from 9/11/20

On:  Friday, 9/11/20, at 9:06am ET   ·   Delayed-Release:  Filing  –  Release Delayed   ·   Accession #:  1213900-20-26174

Previous ‘CORRESP’:  ‘CORRESP’ on 10/30/14   ·   Next:  ‘CORRESP’ on 5/24/23   ·   Latest:  ‘CORRESP’ on 8/1/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/11/20  Adaiah Distribution Inc.          CORRESP10/19/20    1:8K                                     EdgarAgents LLC/FA

Delayed-Release Comment-Response or Other Letter to the SEC
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: CORRESP     Comment-Response or Other Letter to the SEC         HTML      7K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



September 11, 2020

 

VIA EDGAR

 

U.S. Securities & Exchange Commission

Division of Corporation Finance

Office of Transportation and Leisure

100 F Street, NE

Washington, D.C. 20549

Attn: Matthew Crispino

 

Re:Adaiah Distribution

Form 8-K

Filed August 20, 2020

File No. 000-55369

 

Dear Mr. Crispino:

 

On behalf of our client Adaiah Distribution, Inc. (the “Company”), we hereby transmit the Company’s response to the comment letter received from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”), on September 11, 2020, regarding the Current Report on Form 8-K submitted to the Commission on August 20, 2020 (the “8-K”).

 

For the Staff’s convenience, we have repeated below the Staff’s comments in bold, and have followed each comment with the Company’s response.

 

Form 8-K filed August 20, 2020

 

1.It appears that immediately before the transaction with Guangzhou Huaizhong Health Technology Co, Ltd., you were a shell company, as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. Accordingly, please amend your report to provide the information required by Item 2.01(f) of Form 8-K and the related financial information required by Item 9.01 of Form 8-K, or provide us with a detailed analysis of why this disclosure is not required.

 

We note that, as disclosed in the 8-K, Yuantogn Wang acquired the controlling shares in the Company in his individual capacity and Guangzhou Huaizhong Health Technology Co., Ltd was not a party to the transaction. We included disclosure of Mr. Wang’s primary employer and business experience for background purposes only. Accordingly, no amendments to the Company’s financial statements are required as, other than a change in its principal stockholder, officer and director, it’s financial statements and operations remain unchanged.

 

We thank the Staff for its review of the foregoing. If you have further comments, we ask that you forward them by electronic mail to our counsel, Richard Anslow, Esq. at ranslow@egsllp.com or by telephone at (212) 370-1300. 

  

  Sincerely,
   
  /s/ Yuantong Wang
  Yuantong Wang, Chief Executive Officer
  Adaiah Distribution, Inc.

 

cc:Ellenoff Grossman & Schole LLP

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘CORRESP’ Filing    Date    Other Filings
Filed on:9/11/20
8/20/208-K,  SC 14F1
 List all Filings 
Top
Filing Submission 0001213900-20-026174   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 6:56:49.1am ET